Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function

Christina Kunz,1 Doreen Luedtke,1 Anna Unseld,2 Alan Hamilton,3 Atef Halabi,4 Martina Wein,5 Stephan Formella6 1Translational Medicine and Clinical Pharmacology, 2Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany; 3Boehringer Ingelheim, Burli...

Full description

Bibliographic Details
Main Authors: Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:International Journal of COPD
Subjects:
chronic obstructive pulmonary disease
exposure
olodaterol
long-acting β2-agonist
hepatic impairment
renal impairment
Online Access:https://www.dovepress.com/pharmacokinetics-and-safety-of-olodaterol-administered-with-the-respim-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/pharmacokinetics-and-safety-of-olodaterol-administered-with-the-respim-peer-reviewed-article-COPD

Similar Items